3 Companies Creating Revolutionary Technologies of Tomorrow

Innovation often accelerates faster than markets expect. Just a decade ago, self-driving vehicles seemed decades away, genetic medicine remained largely theoretical, and satellite launches required government budgets. However, technological progress can surprise even the most optimistic observers.

Today’s autonomous delivery robots navigate city sidewalks with remarkable precision. The first CRISPR gene editing therapy treats previously incurable diseases. Private companies launch satellites weekly at a fraction of historical costs. Now these technologies are not only viable – they are creating billion-dollar businesses.

Image source: Getty Images.

That’s why three companies leading this revolution deserve your attention right now.

Robots are changing urban delivery

Serve robotics (NASDAQ: SERV) is leading the autonomous delivery revolution: Level 4 curbside robots are redefining last-mile logistics. Their autonomous fleet moves around the city, delivering food and packages for just $1 per delivery—a fraction of the cost of courier delivery. In a market of more than $230 billion, this significant cost advantage provides significant growth.

The company’s release of 2,000 robots by 2025 will be just the beginning. A pioneering partnership with Wing Aviation will combine ground robots and aerial drones to expand delivery reach, while new revenue streams from mobile advertising and technology licensing could accelerate growth as autonomous delivery transforms urban logistics. For investors looking to get early exposure to autonomous technology, Serve offers a rare combination of proven technology and a clear path to profitability.

Engineering breakthroughs in treatment

CRISPR therapy (NASDAQ:CRSP) turned science fiction into medical reality with its gene editing platform. Their breakthrough therapy Casgevy, recently approved to treat devastating blood disorders, represents the first-ever approved CRISPR treatment. With more than $2 billion in cash at the end of the most recent quarter and 35 treatment centers activated worldwide, CRISPR Therapeutics is commercializing a new era in medicine.

The company’s ambitions extend far beyond blood diseases. Their development is aimed at previously “incurable” diseases such as cancer, diabetes and heart disease. This broad platform approach allows CRISPR Therapeutics to potentially revolutionize treatments in many billion-dollar markets as genetic medicine enters its golden age. Early investors have a unique opportunity to back a pioneer in a technology that has the potential to transform modern medicine.

The beginning of the era of commercial space

As SpaceX’s closest competitor in small satellite launches, US Rocket Laboratory (NASDAQ: RCLB) completed 50 successful launches of Electron rockets, a milestone achieved faster than any commercial rocket in history. With second-quarter 2024 revenue reaching a record $106 million and strong growth in launch services and space systems, Rocket Lab USA is turning technical excellence into commercial success.

The recent momentum paints a compelling growth story. The company has 17 new launch contracts in 2024, and the upcoming Neutron rocket is targeting larger payloads. With over $720 million in spacecraft contracts and a space economy projected to reach $1 trillion by 2030, Rocket Lab USA offers investors proven technology and rapidly increasing revenue in commercial space race.

New technological frontier

Serve Robotics, CRISPR Therapeutics, and Rocket Lab USA are pioneering very different technologies with one common theme: each has the potential to fundamentally change trillion-dollar industries. While all three companies face significant headwinds to profitability, they offer investors early access to potentially disruptive technologies.

However, these three stocks are inherently high-risk investments. But for investors willing to embrace volatility, they represent three different ways to invest in technologies that could transform the way goods are delivered, diseases treated and space accessed over the next decade, potentially transforming the lives of early shareholders.

Is it worth investing $1,000 in Serve Robotics right now?

Before you buy Serve Robotics stock, consider this:

Motley Fool Stock Advisor a group of analysts have just determined what they believe is 10 best stocks for investors to buy now… and Serve Robotics wasn’t one of them. The 10 shorted stocks could deliver huge returns in the coming years.

Think when Nvidia compiled this list on April 15, 2005… if you had $1,000 invested at the time of our recommendation, you will have $829,746!*

Stock Advisor provides investors with an easy-to-follow plan for success, including portfolio construction guidelines, regular analyst updates, and two new stock picks every month. Stock Advisor the service has more than four times return of the S&P 500 since 2002*.

View 10 stocks »

*Stock Advisor returns as of November 4, 2024.

George Badwell holds positions at CRISPR Therapeutics and Rocket Lab USA. The Motley Fool has positions and recommends CRISPR Therapeutics and Serve Robotics. The Motley Fool recommends Rocket Lab USA. The Motley Fool has disclosure policy.